Biobanks - 2012 Year Book

  • ID: 2176357
  • July 2012
  • 69 Pages
  • GBI Research
1 of 4

GBI Research, the leading business intelligence provider, has released its latest report, “Biobanks - 2012 Year Book”. It provides key data, information and analysis of 37 of the world’s major biobanks. The report provides information on population-based biobanks, disease based biobanks, brain biobanks, stem cell biobanking, twin registries, children biobanks and many national biobanks. It also provides comprehensive analysis of funding, harmonization, the cost of biobanking, and partnership structure. In addition, the report reviews the factors determining the success and failure of biobanks.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts.

Biobanking is a relatively new field with promising potential. It presents a host of opportunities and challenges. Funding patterns have changed as biobanks have evolved; in a comparative study of more than 100 biobanks around the world, the majority of biobanks were found to be stand-alone, and were entirely funded by the government of the country. Around 70% of biobanks are stand-alone, READ MORE >

Note: Product cover images may vary from those shown
2 of 4

1.1 List of Tables
1.2 List of Figures

2 Introduction

3 Biobanks – The Basics
3.1 Introduction
3.2 Types of Biobanks
3.2.1 DNA Banks
3.2.2 Cell Culture Banks
3.2.3 Pathologically Altered Vital Tissue Banks
3.3 Benefits of Biobanks
3.4 Biobanks - Brief History
3.4.1 Framingham Heart Study
3.4.2 Monitoring of Cardiovascular Diseases Project
3.5 Characteristics of a Biobank
3.6 Classification of Biobanks
3.6.1 Population-Based Biobanks
3.6.2 Disease-Based Biobanks

4 Biobanks – Overview
4.1 Introduction
4.2 National Biobanks
4.3 Funding Structure in Biobanking
4.3.1 Funding Issues
4.3.2 Private Funding
4.3.3 Public-Private Funding
4.3.4 Public Funding
4.4 Partnerships Structure in Biobanking
4.4.1 Comparison of Partnerships
4.5 Increasing Harmonization
4.5.1 Biobanks Participating in Harmonization
4.6 Expert Centers – Trans-national Research
4.7 Cost of Biobanks
4.7.1 Sample Collection
4.7.2 Biobank Set Up
4.7.3 Maintenance of the Biobank
4.7.4 Research Costs
4.7.5 Outreach Activities
4.7.6 Conclusion
4.8 SWOT Analysis of Biobanking Sector
4.8.1 Strengths
4.8.2 Weaknesses
4.8.3 Opportunities
4.8.4 Threats

5 Biobanks – Population-based Biobanks
5.1 Introduction
5.1.1 Cohort study or Panel Study
5.2 deCODE Genetics
5.2.1 Background Information
5.2.2 Organizational Structure
5.2.3 Financial Support
5.2.4 Collaborations
5.2.5 Future Plan
5.3.1 Background Information
5.3.2 Organizational Structure
5.3.3 Financial Support
5.3.4 Collaborations
5.3.5 Future Plan
5.4 UK DNA Banking Network
5.4.1 Background Information
5.4.2 Organizational Structure
5.4.3 Financial Support
5.4.4 Collaborations
5.4.5 Future Plan
5.5 European Network for Genetic and Genomic Epidemiology (ENGAGE)
5.5.1 Background Information
5.5.2 Organizational Structure
5.5.3 Financial Support
5.5.4 Collaborations
5.5.5 Future Plan
5.6 TRANSBIG Network
5.6.1 Background Information
5.6.2 Organizational Structure
5.6.3 Financial Support
5.6.4 Collaborations
5.6.5 Future Plan
5.7 Iceland Health Sector Database
5.7.1 Background Information
5.7.2 Organizational Structure
5.7.3 Financial Support
5.7.4 Collaborations
5.7.5 Future Plan
5.8 Tumor Bank of Castilla-Leon (BTCyL)
5.8.1 Background Information
5.8.2 Organizational Structure
5.8.3 Financial Support
5.9 Telethon Genetic Biobank Network
5.9.1 Background Information
5.9.2 Organizational Structure
5.9.3 Financial Support
5.9.4 Collaborations
5.9.5 Future Plan
5.10 EuroBiobank
5.10.1 Background Information
5.10.2 Organizational Structure
5.10.3 Financial Support
5.10.4 Collaborations
5.10.5 Future Plan
5.11 Latvian Biobank
5.11.1 Background Information
5.11.2 Organizational Structure
5.11.3 Financial Support
5.11.4 Collaborations
5.11.5 Future Plan
5.12 Canadian Partnership for Tomorrow Project
5.12.1 Background Information
5.12.2 Organizational Structure
5.12.3 Financial Support
5.12.4 Collaborations
5.12.5 Future Plan

6 Biobanks – Disease-Based Biobanks
6.1 Introduction
6.2 Cancer Biobanks
6.2.1 Victorian Cancer Biobank
6.2.2 The Ontario Tumor Bank
6.2.3 The Canadian Tumor Repository Network
6.2.4 Tumor Tissue Repository
6.3 Brain Biobanking
6.3.1 Huddinge Brain Biobank
6.3.2 MRC London Brain Bank for Neurodegenerative Diseases
6.3.3 The MRC HIV Brain and Tissue Bank
6.3.4 The MRC Sudden Death Brain and Tissue Bank
6.3.5 CJD Brain and Tissue Bank
6.3.6 UK Multiple Sclerosis Tissue Bank
6.3.7 South West Dementia Brain Bank
6.3.8 Queen Square Brain Bank for Neurological Disorders
6.3.9 Newcastle Brain Tissue Resource
6.4 Twin Registries
6.4.1 GenomEUTwin
6.4.2 The Australian Twin Registry
6.4.3 The Mid-Atlantic Twin Registry
6.5 Stem Cell Biobanking
6.5.1 The Singapore Stem Cell Consortium
6.5.2 Coriell Stem Cell Biobank
6.5.3 Swiss Stem Cells Bank
6.6 Children Biobanks
6.6.1 The Norwegian Mother and Child Cohort Study (MoBa)
6.6.2 Avon Longitudinal Study of Parents and Children (ALSPAC)
6.7 Largest Biobanks and Biobanking Networks in the World
6.7.1 The Public Population Project in Genomics (P3G)
6.7.2 Estonian Genome Project (EGP)
6.7.3 Singapore Tissue Network
6.7.4 UK Biobank
6.7.5 International Genomics Consortium (IGC)

7 Biobanks – Regulatory and Ethical Issues and Challenges
7.1 Introduction
7.2 Issues Related to Biobanking
7.2.1 Informed Consent
7.2.2 Confidentiality
7.2.3 Returning Results from Biobank
7.2.4 Secondary Use of Samples Collected Over Time
7.3 Challenges Faced by Biobanks
7.4 Conclusions

8 Biobanks – Appendix
8.1 Market Definitions
8.2 Abbreviations
8.3 Sources
8.4 Research Methodology
8.4.1 Coverage
8.4.2 Secondary Research
8.4.3 Primary Research
8.4.4 Expert Panel Validation
8.5 Contact Us
8.6 Disclaimer

1.1 List of Tables

Table 1: Comparison of Funding Sources for Eight Major Biobanks - 2010
Table 2: Biobanks, International Biobanks involved in Harmonization Programs
Table 3: Biobanks, Applications and Strengths of Population-based Biobanks
Table 4: Biobanks, deCODE Genetics Overview
Table 5: Biobanks, CARTaGENE Overview
Table 6: Biobanks, Type and Number of Sample Collections Available at UKDBN- 2010
Table 7: Biobanks, UK DNA Banking Network Overview
Table 8: Biobanks, European Network for Genetic and Genomic Epidemiology Overview
Table 9: Biobanks, TRANSBIG Network Overview
Table 10: Biobanks, Iceland Health Sector Database Overview
Table 11: Biobanks, Biobanks with Sample Sizes of =200,000, 2010
Table 12: Biobanks, Largest Children Biobank Projects around the World - 2010

1.2 List of Figures

Figure 1: Biobanks, Global, Anticipated Benefits
Figure 2: Biobanks, Global, Type of Data and Sources Obtained from Biobanks
Figure 3: Biobanks, Classification: Type of Sample Availability
Figure 4: Biobanks, Type of Partnerships, Europe (%), 2010
Figure 5: Biobanks, Ownership of Biobanks, Europe, 2010
Figure 6: Biobanks, Global, Expert Centers Facilitating Trans-national Research
Figure 7: SWOT Analysis of Biobanking Sector
Figure 8: Biobanks, ENGAGE, Funding Sources (%) - 2011
Figure 9: Biobanks, TRANSBIG, Network Funding Sources (%) - 2011
Figure 10: Biobanks, EuroBiobank, Main Objectives - 2011
Figure 11: Biobanks, Frequency of Registrants by Age at Mid-Atlantic Twin Registry - 2011
Figure 12: Biobanks, Major Issues Threatening Biobanks - 2011

Note: Product cover images may vary from those shown
3 of 4

Biobank Boom Damaged by Lack of Tissue Samples.

The increase in the number of biobanks around the world has played an important role in fostering drug discovery, but tissue sample availability and limited inter-facility co-operation is threatening to hamper further progress, warns a new report by healthcare industry experts GBI Research.

According to the report*, biobanks have multiplied significantly since the 1970’s, and have become integral to research facilities around the globe. The period 1990-1999 saw the most significant percentage increase, at 42%. Growth in 2000 to 2009 was almost as impressive, with a 36% increase in biobanks.

These bio-repositories have become increasingly important with the expanding popularity of contemporary research into personalized medications and genomics, but a lack of particular storage types and specific tissue samples are major issues affecting the effectiveness of biobanks worldwide.

Tumor Tissue Repositories (TTR), for example, are a source of brain tumor samples that are experiencing difficulties in terms of supply. Normal brain samples to be used as control subjects are lacking, making comparative study ever more difficult.

However, there is an ongoing push toward harmonization – the large-scale sharing of data and statistical analyses that is allowing bio-repositories to benefit from the resources of others.

According to GBI Research, fruitful analyses will depend on the ability to harmonize and standardize the collection, storage, and management of data and bio-samples across biobanking studies.

Yet, while many international biobanks, such as P3G (Public Population Program in Genomics), BBMRI (Biobanking and BioMolecular Resources Research Infrastructure) and UKDBN (United Kingdom DNA Banking Network), are already involved in harmonization programs, several biobanks are still to join.

GBI Research states that, out of over 100 biobanks, the majority of facilities are stand-alone and receive all of their funding from the government. These made up 68% of the global total for 2010, while the remaining 32% were partnered with other biobanks or institutions.

* Biobanks - 2012 Year Book

This report provides key data, information and analysis of 37 of the world’s major biobanks. It also provides information on population-based biobanks, disease based biobanks, brain biobanks, stem cell biobanking, twin registries, children biobanks and many national biobanks.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown


  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.


If you have a more general question about our products please try our



Our Clients

  • Amgen Inc.
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • Beckman Coulter, Inc.
  • Novartis AG
  • Baxter International Inc.